Souhaitez-vous accéder aux communiqués récents ?

ORION CORPORATION PRESS RELEASE 30 MAY 2026 at 21:30 EEST         Orion Pharma announces first results from Phase 1/2 TEADES trial with TEAD inhibitor ODM-212 in patients with advanced solid...

ORION OYJ        LEHDISTÖTIEDOTE        30.5.2026 KLO 21.30         Orion Pharma julkisti ensimmäiset tulokset Faasi 1/2 TEADES-tutkimuksesta ODM-212-molekyylillä (TEAD-estäjä) potilailla, joilla...

MannKind Announces FDA Approval of Afrezza® the 1st & Only Inhaled Mealtime Insulin for Use in Children & Adolescents Aged 6 and Older Living with Diabetes

Taurus Meds online TRT claims and Taurus Charge 4-in-1 ED evaluated: $49 intake, $149/mo TRT, $129.90 sublingual ED, clinician-prescribed.

SOUTH SAN FRANCISCO, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver...

THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies...

EscharEx® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue...

SOUTH SAN FRANCISCO, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver...

Dublin, May 26, 2026 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Asia Beyond China: Pharma R&D and Deal Trends in South Korea, Japan, and India" report has been added to ...

Dublin, May 26, 2026 (GLOBE NEWSWIRE) -- The "Pharma 4.0 Market Size, Share & Trends Analysis Report by Type, Technology, Application, End Use, Region, and Growth Forecasts, 2026-2033" has been...